['Therapeutic strategy for prostate cancer is decided according to T\xa0stage, Gleason score, and prostate-specific antigen (PSA) level. These clinical factors are not accurate enough to predict individual risk of local failure of prostate cancer after radiotherapy. Parameters involved with radiosensitivity are required to improve the predictive capability for local relapse.', 'We analyzed 58\xa0patients with localized adenocarcinoma of the prostate between August 2007 and October 2010 treated with 76\xa0Gy of intensity-modulated radiotherapy (IMRT) as a\xa0discovery cohort and 42\xa0patients between March 2001 and May 2007 treated with three-dimensional conformal radiotherapy (3D-CRT) as a\xa0validation cohort. Immunohistochemical examination for proteins involved in nonhomologous end-joining was performed using biopsy specimens.', "Ku70 expression was not correlated with various clinical parameters, such as the Gleason score and D'amico risk classification, indicating that Ku70 expression was an independent prognostic factor. The predictive value for PSA relapse was markedly improved after the combination of Gleason score and Ku70 expression, as compared with Gleason score alone. In patients treated with radiotherapy and androgen deprivation therapy (ADT), no relapses were observed in patients with Gleason score ≤7 or low Ku70 expression. In contrast, patients with Gleason score ≥8 and high Ku70 expression had high PSA relapse rates. In the validation cohort, similar results were obtained."] Does expression of Ku70 predict results of radiotherapy in prostate cancer?